Erica Stringer-Reasor Selected Research

trebananib

12/2023

Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Erica Stringer-Reasor Research Topics

Disease

12	Neoplasms (Cancer) 01/2023 - 06/2017
11	Breast Neoplasms (Breast Cancer) 12/2023 - 06/2017
7	Triple Negative Breast Neoplasms 01/2023 - 08/2018
4	Pathologic Complete Response 12/2022 - 01/2020
2	Neoplasm Metastasis (Metastasis) 01/2022 - 06/2017
2	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 08/2019
1	Microsatellite Instability 01/2022
1	Circulating Neoplastic Cells 01/2022
1	Hyperglycemia 10/2021
1	Nausea 01/2021
1	Alopecia (Baldness) 01/2021
1	Brain Neoplasms (Brain Tumor) 01/2021
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021
1	Fatigue 01/2021
1	Headache (Headaches) 01/2021
1	Neutropenia 01/2021
1	Vomiting 01/2021
1	Carcinoma (Carcinomatosis) 08/2019

Drug/Important Bio-Agent (IBA)

8	Biomarkers (Surrogate Marker)IBA 12/2023 - 06/2017
7	Hormones (Hormone)IBA 12/2023 - 08/2018
3	ErbB Receptors (EGF Receptor)IBA 01/2023 - 01/2020
3	pembrolizumabIBA 01/2022 - 08/2019
2	Trastuzumab (Herceptin)FDA Link 12/2023 - 01/2021
2	Paclitaxel (Taxol)FDA LinkGeneric 12/2023 - 10/2021
2	gedatolisibIBA 01/2023 - 01/2023
2	Fulvestrant (Faslodex)FDA Link 01/2023 - 01/2022
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2022 - 01/2020
2	PlatinumIBA 01/2021 - 08/2019
1	trebananibIBA 12/2023
1	Cisplatin (Platino)FDA LinkGeneric 01/2023
1	Cyclin-Dependent Kinase 4IBA 01/2023
1	exemestane (Aromasin)FDA Link 01/2023
1	dacomitinibIBA 01/2023
1	Docetaxel (Taxotere)FDA Link 01/2023
1	ribociclibIBA 01/2023
1	STA 9090IBA 12/2022
1	CateninsIBA 01/2022
1	dostarlimabIBA 01/2022
1	Immune Checkpoint InhibitorsIBA 01/2022
1	AlpelisibIBA 01/2022
1	Circulating Tumor DNAIBA 01/2022
1	Metformin (Glucophage)FDA LinkGeneric 10/2021
1	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2021
1	ganitumabIBA 10/2021
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2021
1	Hemoglobins (Hemoglobin)IBA 10/2021
1	Capecitabine (Xeloda)FDA Link 01/2021
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2021
1	cofetuzumab pelidotinIBA 01/2021
1	Immunoconjugates (Immunoconjugate)IBA 01/2021
1	tucatinibIBA 01/2021
1	MK 2206IBA 01/2020
1	TOR Serine-Threonine KinasesIBA 01/2020
1	niraparibIBA 08/2019
1	Bevacizumab (Avastin)FDA Link 08/2019
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 08/2019
1	Poly Adenosine Diphosphate RiboseIBA 08/2019
1	MicroRNAs (MicroRNA)IBA 06/2017
1	Tumor Biomarkers (Tumor Markers)IBA 06/2017

Therapy/Procedure

8	Therapeutics 01/2023 - 01/2020
6	Neoadjuvant Therapy 12/2022 - 08/2018
4	Drug Therapy (Chemotherapy) 12/2023 - 08/2019
1	Investigational Therapies (Experimental Therapy) 12/2023
1	Adjuvant Chemotherapy 01/2020